Skip to content

Deferred income at other companies

MPLX logo
MPLXMPLX
$115M-63.7%
Arteris, Inc. logo
Arteris, Inc.AIP
$6.16M-16.1%
Arthur J. Gallagher logo
Arthur J. GallagherAJG
$177M+167%
Williams Companies logo
Williams CompaniesWMB
$170M+6.9%
UnitedHealth Group logo
UnitedHealth GroupUNH
$3.42B+3.7%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$6.6M

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.39B+78.5%

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's deferred income?
Aurinia Pharmaceuticals (AUPH) reported deferred income of $12.41M in Q1 2026.
How has Aurinia Pharmaceuticals's deferred income changed year-over-year?
Aurinia Pharmaceuticals's deferred income decreased by 0.3% year-over-year, from $12.45M to $12.41M.